FLAiRE™: Real-Time Inflammation Tracking
The world's first software platform that continuously monitors inflammation—the hidden driver behind 3 in 5 global deaths—without invasive blood tests.
Join The Waitlist
The Silent Epidemic: Chronic Inflammation
60%
Global Deaths
According to the WHO, 3 in 5 deaths worldwide are linked to inflammatory diseases.
$110B
Annual Loss
Employers lose billions yearly to inflammation-related conditions, as reported by RAND.
Reactive
Current Testing
Today's standard—hs-CRP blood tests—is invasive, infrequent, and comes too late.
50M+
Chronic Sufferers
Over 50 million Americans live with chronic inflammatory conditions requiring ongoing management.
Introducing FLAiRE™: Continuous Inflammation Monitoring
Software-Only, Device-Agnostic Precision Biomarker Ai Platform
FLAiRE™ transforms existing wearable devices into powerful inflammation monitors, delivering a real-time Continuous Inflammation Score (0-100) with personalized feedback within 5 minutes of detecting a spike.
Our proprietary AI engine analyzes multiple data streams including heart rate variability, skin temperature, and contextual factors like stress and nutrition to provide actionable insights.
How FLAiRE™ Works
Data Collection
Captures HRV, skin temperature, electrodermal activity, and motion from existing wearable devices.
AI Processing
Proprietary algorithms analyze multimodal data against our database of over 1 million hours of data and 25,000 lab samples.
Actionable Insights
Delivers personalized recommendations within 5 minutes of detecting an inflammatory spike.
Proven Technology & Defensibility
Robust Data Foundation
Our platform is built on over 1 million hours of multimodal data, including 25,000 laboratory samples that validate our approach to non-invasive inflammation monitoring.
Patent-Protected Innovation
Three provisional patents filed covering our ensemble model architecture, proprietary calibration routine, and innovative trigger attribution system.
Universal Compatibility
Our SDK works seamlessly across all major wearable platforms, including watchOS, Wear OS, and Garmin, ensuring maximum market penetration.
Clinical Validation
82%
Accuracy Rate
Initial pilot study with 500 participants demonstrated strong correlation with traditional hs-CRP levels, achieving an AUC of 0.82.
5min
Response Time
FLAiRE™ provides personalized feedback within 5 minutes of detecting an inflammatory spike, compared to days or weeks with traditional testing.
24/7
Continuous Monitoring
Unlike point-in-time blood tests, our platform provides continuous inflammation tracking to identify patterns and triggers.
Multi-Channel Products & Services
B2B Wellness
$1 per user per month, targeting self-insured employers and corporate wellness programs seeking to reduce healthcare costs.
SDK Licensing (B2B2C)
$1 per user per month, enabling third-party health apps and wearable manufacturers to incorporate our inflammation tracking technology.
B2C App
Freemium model with basic inflammation tracking free and premium features at $9.99 per month, including personalized interventions.
World-Class Founding Team
Prof. Matt Riemann
Founder of Shae Group and pioneer in precision human intelligence with extensive experience developing precision health technologies. Matt brings cutting-edge expertise in Ai for predictive and preventative healthcare.
Dr. KellyAnn Petrucci
New York Times bestselling author with a following of 3.6M health-conscious consumers and 2M+ customers. Dr KellyAnn brings market credibility and a powerful distribution channel for consumer adoption.
World Class Advisory Network
Our team is supported by a robust network of university researchers, clinical practitioners, and high-net-worth stakeholders invested in transforming inflammatory disease and its associated burden on our healthcare systems and lives.
Join The FLAiRE™ Revolution
1
H2 2025
Expanded clinical trials with major research institutions to further validate our technology across diverse populations.
2
H1 2026
Beta launch with selected corporate wellness partners and early SDK integration with leading health apps.
3
H2 2026
Full commercial launch of FLAiRE™ platform across all channels, revolutionizing how we monitor and manage inflammation.